"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA GRANTED REGULAR APPROVAL TO ENASIDENIB (IDHIFA) FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH AN ISOCITRATE DEHYDROGENASE-2 MUTATION

FDA GRANTED REGULAR APPROVAL TO ENASIDENIB (IDHIFA) FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH AN ISOCITRATE DEHYDROGENASE-2 MUTATION

07 Aug 2017 9:03 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted regular approval to enasidenib (IDHIFA, Celegene) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydropgenase-2 (IDH2) mutation as detected by an FDA-approved test. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software